Keele Research Repository

Article

Moss, DM, Curley, P, Kinvig, H, Hoskins, C ORCID: https://orcid.org/0000-0002-7200-0566 and Owen, A (2018) The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. Expert Review of Gastroenterology and Hepatology, 12 (3). pp. 223-236.

Curley, P, Giardiello, M, Liptrott, NJ, Dickens, D, Moss, DM, Hobson, J, Savage, AC, McDonald, T, Siccardi, M, Rannard, S and Owen, A (2017) In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine, 2 (3). pp. 157-169.

Curley, P, Rajoli, RK, Moss, DM, Liptrott, NJ, Letendre, S, Owen, A and Siccardi, M (2016) Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. Antimicrobial Agents and Chemotherapy, 61 (1).

Curley, P, Moss, DM, Siccardi, M and Owen, A (2016) Development and Validation of a LC-MS/MS Assay for the Quantification Of Efavirenz In Different Biological Matrices. Bioanalysis, 8 (20). pp. 2125-2134.

Moss, DM, Curley, P, Shone, A, Siccardi, M and Owen, A (2014) A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy, 69 (12). pp. 3275-3281.

Moss, DM, Liptrott, NJ, Curley, P, Siccardi, M, Back, DJ and Owen, A (2013) Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro. Antimicrobial Agents and Chemotherapy, 57 (11). pp. 5612-5618.